Intuitive Surgical (NSDQ:ISRG) topped Wall Street’s expectations for its 4th-quarter sales, sending share prices up today ahead of CEO Gary Guthart’s presentation at the J.P. Morgan Healthcare conference.
J.P. Morgan Healthcare Conference
Edwards promises to ‘meet force with force’ in defending its TAVI footprint
Medtronic CEO: Value-based healthcare is the only way to save medtech
There’s been a lot of hand-wringing in medtech as healthcare systems around the world have moved from fee-for-service to value-based healthcare models that reward for outcomes, rather than for specific procedures.
St. Jude CEO: Medtronic’s renal denervation miss doesn’t dampen our spirits
Thoratec responds to NEJM blood clot report
Covidien CEO: Emerging markets a priority
FDA OKs new trial for Edwards Lifesciences heart valve
Edwards Lifesciences (NYSE:EW) said it won an investigational device exemption from the FDA to run a clinical trial of its Sapien 3 replacement heart valve in intermediate-risk patients.
Volcano lowers 2014 guidance, shares slide
St. Jude Medical beats guidance with Q4 prelims
ArthroCare updates on remaining federal issues
ArthroCare (NSDQ:ARTC) president & CEO David Fitzgerald provided highlights on the company’s ongoing beef with federal investigators, telling an audience at the J.P. Morgan healthcare conference in San Francisco this week that at least 1 of the pair of remaining legacy issues may be closing soon.
St. Jude defends Durata amid FDA warning at manufacturing facility
St. Jude Medical‘s (NYSE:STJ) implanted cardiac device market share is in great shape despite ongoing issues with its high-voltage defibrillator leads, CEO Daniel Starks told an audience at the J.P. Morgan healthcare conference last night.